Chordate Medical Holding AB (publ) ("Chordate Medical" or the "Company") announces that the directed set-off issue to underwriters who have chosen to receive guarantee compensation in the form of newly issued shares in the Company announced on January 18, 2023 (the "Compensation Issue") has been registered with the Swedish Companies Registration Office (sw. “Bolagsverket”). Distribution of shares is expected to commence on January 25, 2023.
Financial and legal advisers
Västra Hamnen Corporate Finance AB acts as financial adviser and Wistrand Advokatbyrå acts as legal adviser to Chordate Medical in connection with the Compensation Issue.
The information was submitted, through the contact person above, for publication on January 24 at 19.20 2023 (CET).
For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277
About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked a neuromodulation and drug-free treatment technology for chronic migraine and chronic nasal congestion (rhinitis), Kinetic Oscillation Stimulation (K.O.S). The K.O.S-treatment has clinically proven efficacy according to scientific studies. The company's products are available via distributors to clinics in the Nordic countries, Germany, the UK, Italy, Israel, and Saudi Arabia. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at chordate.com/en
The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.
N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.